CD8A and metastatic neoplasm: Foxp3, a marker of Tregs, was substantially decreased, and CD8 (+), a marker of cytotoxic T lymphocytes, was substantially increased in anti-TGF-β antibody-treated groups in metastatic tumor lesions.